Applications of (R)-3-Amino-4-(3-Methylphenyl)Butanoic Acid Hydrochloride in Industrial Manufacturing

(R)-3-Amino-4-(3-Methylphenyl)Butanoic Acid Hydrochloride supports specialized synthesis workflows in pharmaceutical and advanced chemical manufacturing. Our material integrates into strictly regulated downstream use cases, providing customized chemical functionalities for high-value applications. Below, we outline key downstream scenarios where this material plays a distinctive role, presenting detailed compliance, process, and product information specific to each use.

1. Chiral Building Block in Anticonvulsant API Synthesis

This compound functions as a critical chiral starting material during the production of certain anticonvulsant drug substances. Manufacturers rely on its stereospecificity during enantioselective synthesis steps to construct active pharmaceutical ingredients (APIs) that target neurological conditions. The raw material is integrated following strict quality and purity protocols to ensure patient safety and regulatory compliance.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Part II: Basic Requirements for Active Substances
• USP/NF Monographs for related enantiomeric compounds
• FDA 21 CFR Part 211: Drug Product Quality System Regulations

Typical usage ratio

• Applied at 1.2–2.0 molar equivalents relative to downstream reactant, adjusted according to target API yield and chiral purity requirements.

Downstream process integration

• Material introduced during asymmetric amination or amidation as the first dedicated chiral intermediate in multi-step API synthesis from protected aromatic precursors.

Final product types

• Gabapentinoid API intermediates
• Final anticonvulsant drug substances
• Chiral reference standards for pharmaceutical QC

2. Chemical Intermediate in Peptidomimetic Synthesis

Downstream peptide and peptidomimetic manufacturers utilize this molecule to provide tailored side chain modification. Its substitution pattern allows the engineering of analogs with improved binding affinities and pharmacokinetics compared to natural peptides, targeting applications in therapeutics and research tool compounds.

Industry compliance standards

• ISO 9001:2015 Quality Management for Chemical Synthesis
• IPEC-PQG GMP Guide for Pharmaceutical Excipients
• REACH Regulation (EC) No 1907/2006, Annex VII
• Ph. Eur. 2.2.40: Amino Acid Analysis

Typical usage ratio

• Incorporated at 0.5–2.5% (w/w) of total solid-phase load, adjusted for desired peptidomimetic segment length and sequence composition.

Downstream process integration

• Direct coupling onto the resin during solid-phase peptide synthesis (SPPS) via activated ester amidation before chain extension or cyclization steps.

Final product types

• Synthetic peptide analogs with aromatic side chain modifications
• Therapeutic peptidomimetic candidates in clinical trials
• Peptide-based research tools for receptor affinity assays

3. Key Intermediary in Small Molecule CNS Modulator Development

Specialty pharmaceutical companies employ this hydrochloride as an advanced intermediate for creating novel central nervous system (CNS) active agents. Its combination of chiral amino and aromatic substituent groups lends itself to the synthesis of proprietary scaffolds, supporting medicinal chemistry programs focused on improving selectivity and metabolic stability.

Industry compliance standards

• FDA 21 CFR Part 210: GMP for Manufacturing, Processing, and Holding of Drugs
• OECD Guidelines for Testing of Chemicals: Section 4 (Neurotoxicity)
• ICH Q3A/B: Impurities in New Drug Substances/Products
• ICH M7: Assessment and Control of DNA Reactive Impurities

Typical usage ratio

• Ranges from 0.02–0.1 molar equivalents per total batch cycle; empirical adjustment based on scaffold complexity and downstream functionalization requirements.

Downstream process integration

• Employed as a nucleophilic amine precursor during reductive amination steps in CNS modulator synthetic routes involving arylation, alkylation, or heterocyclic ring closure.

Final product types

• Preclinical CNS-active compound libraries
• Patent-protected small molecule clinical trial materials
• Validated CNS drug discovery reagents

4. Raw Material for GMP Reference Standards Production

Certified analytical laboratories integrate this compound into processes for manufacturing fully characterized chemical reference standards. Regulatory agencies and pharmaceutical QC groups require primary and secondary reference substances with documented chiral purity and batch traceability, supporting method validation and product release testing.

Industry compliance standards

• ISO/IEC 17025: Testing and Calibration Laboratories
• USP General Chapter <1224>: Reference Standards
• Ph. Eur. 5.12: Reference Standards
• FDA Guidance for Industry: Analytical Procedures and Methods Validation

Typical usage ratio

• Used as 100% starting material base for single-component reference standard preparation; mass adjusted to targeted certification batch size (typically 1–5 g per lot).

Downstream process integration

• Material purified by chiral HPLC and subjected to full spectroscopic characterization (NMR, LC-MS, IR) before packaging under controlled conditions for traceable QC supply chains.

Final product types

• Certified pharmaceutical reference standards
• Secondary reference stocks for batch release testing
• Analytical standards for impurity profiling in finished dosage forms